Zanubrutinib monotherapy continuous for r/r WM (ASPEN schedule) — alternative to ibrutinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ZANUBRUTINIB |
|---|
| ID | REG-ZANUBRUTINIB-WM-RELAPSED |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-WM-2024 SRC-NCCN-BCELL-2025 |
Notes
ASPEN trial (Tam 2020, follow-up 2023): r/r WM (and 1L cohort) — zanubrutinib superior to ibrutinib in safety profile (afib 2.6% vs 15.3%; cardiac death 0% vs 1.6%; major bleeding 4% vs 9%; hypertension 13% vs 25%); comparable VGPR-or-better hematologic response (28% vs 19% in MYD88-mut cohort, numerically superior). Preferred BTKi for r/r WM where accessible. CXCR4-WHIM-mutated subset has reduced depth of response with both BTKis — consider proteasome-inhibitor (carfilzomib) alternative for these patients.
Used By
Indication
IND-WM-2L-ZANUBRUTINIB- IND-WM-2L-ZANUBRUTINIB